77 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Jan 24
Regulation FD Disclosure
10:29am
USE
Reblozyl: Significant growth opportunities in MDS-associated anemia and beyond Ongoing registrational studies 1L TD myelofibrosis(INDEPENDENCE
8-K
EX-1.1
BMY
Bristol-Myers Squibb Co.
13 Nov 23
Other Events
4:19pm
Investments, Inc.
PNC Capital Markets LLC
CAVU Securities, LLC
Drexel Hamilton, LLC
Independence Point Securities LLC
*We expect that delivery … Hamilton, LLC
Independence Point Securities LLC
Total
II-2
SCHEDULE III
Schedule III(a) Issuer Free Writing Prospectuses not included in the Pricing
424B5
66yxmmyv 82x4
1 Nov 23
Prospectus supplement for primary offering
4:16pm
FWP
tlymqtb8
30 Oct 23
Free writing prospectus
5:26pm
8-K
EX-99.2
tjiqgxwxt
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
yqu98blc01p
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.2
87vd3nzr tu9j
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
g0ndo
4 May 23
Departure of Directors or Certain Officers
4:48pm
8-K
EX-99.2
klr6k1f
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
DEFA14A
n3hvp3cw9f91
10 Apr 23
Additional proxy soliciting materials
5:12pm
8-K
EX-99.3
o5zume
26 Oct 22
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
7:48am
8-K
EX-99.3
5v8kf 3lb
27 Jul 22
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
7:44am
8-K
e5lv3b5vgn2
15 Jun 22
Departure of Directors or Certain Officers
4:29pm
8-K
EX-99.3
lax0utibmmv118
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
1ka e79u1s
20 Apr 22
Additional proxy soliciting materials
4:30pm
PX14A6G
ueoskb xmy5
5 Apr 22
Letter to shareholders
4:53pm